Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514601 | 0.92 | SMPD1 (0.38) | NR1H4HRH3SMPD1MEN1KMT2A | |
| SCHEMBL4508885 | 0.89 | ALDH1A1 (0.40) | MEN1KMT2AGCK | |
| SCHEMBL1573173 | 0.82 | NR1H4 (0.42) | NR1H4HRH3AKR1C2AKR1C1SMPD1 | |
| SCHEMBL13918727 | 0.82 | ALDH1A1 (0.38) | MEN1KMT2A | |
| SCHEMBL4502430 | 0.82 | NR1H4 (0.42) | NR1H4SMPD1KMT2A | |
| SCHEMBL1573171 | 0.81 | NR1H4 (0.42) | NR1H4HRH3AKR1C2AKR1C1SMPD1 | |
| SCHEMBL1932569 | 0.79 | KMT2A (0.46) | MEN1KMT2A | |
| SCHEMBL4518703 | 0.78 | KMT2A (0.41) | NR1H4AKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL4518702 | 0.77 | MEN1 (0.38) | NR1H4AKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL1573416 | 0.76 | ALDH1A1 (0.38) | NR1H4AKR1C2AKR1C1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | NR1H4 209/4885HRH3 536/4885AKR1C2 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.